All posts by: Michael Zand

About Michael Zand

Researchers develop new way to develop purer insulin-producing stem cells – Diabetes.co.uk

Continue reading

2017-08-01 NEWS

Researchers develop new way to develop purer insulin-producing stem cells
Diabetes.co.uk
The future of type 1 diabetes treatment is likely to come from living cells that can produce and release insulin inside the person’s body. In recent years, scientists have been using new techniques to allow human stem cells to grow an unlimited number

Continue reading

2017-08-01 NEWS

Researchers develop new way to develop purer insulin-producing stem cells
Diabetes.co.uk
The future of type 1 diabetes treatment is likely to come from living cells that can produce and release insulin inside the person’s body. In recent years, scientists have been using new techniques to allow human stem cells to grow an unlimited number

Continue reading

2017-08-01 NEWS

High school student gets an early start in stem cell research at USC
USC News
More impressively, he was familiar with these terms before starting his summer internship in the lab of Andy McMahon, kidney researcher and director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. “I knew I …

Continue reading

2017-08-01 NEWS

USC News

High school student gets an early start in stem cell research at USC
USC News
More impressively, he was familiar with these terms before starting his summer internship in the lab of Andy McMahon, kidney researcher and director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. “I knew I …

Continue reading

2017-08-01 NEWS

FierceBiotech

News of Note—New CRISPR R&D head; Homology $83.5M raise; Cellectar collab
FierceBiotech
After jumping ship from a troubled AstraZeneca, its former head of oncology, Tony Ho, M.D., has climbed aboard preclinical gene editing biotech CRISPR Therapeutics. He becomes EVP and head of R&D at the company and will oversee its global research …

Continue reading

2017-08-01 NEWS

Chiesi Ends Collaboration with uniQure on Hemophilia B Gene Therapy Candidate
Genetic Engineering & Biotechnology News
Chiesi Group has ended its four-year-old collaboration with uniQure to co-develop and license a gene therapy for hemophilia B and has returned its development and commercialization rights to the gene therapy candidate in Europe and other areas, uniQure …

and more »

Continue reading

2017-08-01 NEWS

Increased α5β1 integrin could improve tumor cell-killing performance in geriatric patients
EurekAlert (press release)
This report showed that CART cells from geriatric donors have specific defects that lead to decreased tumor cell-killing performance, when compared to younger donors. The study also uncovered the Geri-T method, which increases α5β1 integrin expression …

Continue reading

2017-08-01 NEWS

Berkeley Files Opening Brief in CRISPR Appeal
JD Supra (press release)
In considering the evidence before it, the PTAB gave great weight to contemporaneous, cautious statements in the art in view of Professor Doudna’s disclosure of in vitro CRISPR activity regarding whether the system would work in eukaryotic cells